From Yahoo Finance: 2025-03-22 16:04:00

CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK) have both experienced significant stock declines in the past year, with CRISPR down 41% and Merck down 22%. Despite challenges, CRISPR’s gene-editing therapy Casgevy is gaining traction, with approval in multiple regions, offering a substantial market opportunity. The potential for clinical success and increased sales makes both stocks appealing to patient investors.

CRISPR Therapeutics’ Casgevy, a gene-editing therapy for rare blood diseases, has received approval in the U.S., the U.K., and the European Union, among other regions. The therapy’s high cost and potential market size, enhanced by a partnership with Vertex Pharmaceuticals, position CRISPR for future revenue growth. Additionally, CRISPR is developing other innovative gene-editing medicines, further adding to its potential for success.

Merck’s top-selling drug, Keytruda, faces potential competition from an investigational cancer treatment, ivonescimab, which outperformed Keytruda in a recent clinical trial. Keytruda accounts for a significant portion of Merck’s revenue, making its patent expiration in 2028 a concern. Merck is strategizing post-Keytruda plans, including extending Keytruda’s patent life and developing new medicines to maintain its market standing.

Despite recent stock declines, both CRISPR Therapeutics and Merck present opportunities for long-term investors. CRISPR’s innovative therapies and expanding market reach, along with Merck’s strategic post-Keytruda plans and diverse product pipeline, indicate potential for future growth. Patient investors may find value in these beaten-down stocks for their long-term investment portfolios.



Read more at Yahoo Finance: 2 Beaten-Down Stocks to Buy on the Dip